Genalyte
Genalyte is a San Diego life sciences company developing the Merlin automated point-of-care diagnostic system, powered by its proprietary Maverick silicon photonic microring resonator biosensor platform, to deliver lab-quality blood test results in under 30 minutes to clinics, hospitals, and other healthcare providers.
- Company typePrivate
- Founded2007
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genalyte does
Genalyte is a San Diego-based life sciences company founded in 2007 that develops the Merlin automated diagnostic system, a point-of-care platform combining chemistry analysis, hematology analysis, and the proprietary Maverick immunoassay analyzer built on silicon photonic microring resonator technology. Each Maverick chip supports dozens of label-free immunoassays using over 100 micro-scale rings, eliminating the need for fluorescent or enzymatic labels while enabling multiplex detection from a single small sample. The Merlin device delivers comprehensive lab-quality results — covering CBC, lipid panels, and comprehensive metabolic panels — in under 30 minutes, with up to 20 vials processed fully automatically without plumbing requirements.
The company operates a three-tier business model: hardware sales of the Merlin device, recurring revenue from reagents and consumables used with the system, and subscription/recurring revenue potential from the CloudLab EMR-integration platform. Revenue is not yet generated as Merlin is pending FDA 510(k) clearance; only individual assays (TSH, RNP) and an EUA for SARS-CoV-2 have been cleared to date. The company has raised over $67 million in Series C financing led by Verily Life Sciences (Alphabet) and Boutique Venture Partners, with a cumulative funding history exceeding $150 million across multiple rounds.
Genalyte targets a horizontal set of point-of-care segments including primary care clinics, concierge clinics, hospitals and health systems, surgery centers, government/military/VA facilities, and veterinary clinics. The go-to-market combines enterprise field sales targeting healthcare networks (exemplified by a Letter of Intent with Burjeel Holdings for MENA deployment) with product-led demand capture through the company website. The company holds 31+ patents and has produced 48 peer-reviewed publications supporting its technology platform.
Genalyte firmographics
Firmographics- Name
- Genalyte
- Legal name
- GENALYTE, INC.
- Website
- https://genalyte.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Genalyte is a San Diego life sciences company developing the Merlin automated point-of-care diagnostic system, powered by its proprietary Maverick silicon photonic microring resonator biosensor platform, to deliver lab-quality blood test results in under 30 minutes to clinics, hospitals, and other healthcare providers.
- Ownership category
- akta.pro rank
Genalyte industry classification
Industry- Product category
- Point-of-Care Diagnostic Systems
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Genalyte is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Genalyte business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Merlin Diagnostic Device Sales: Genalyte generates revenue through the sale of its Merlin automated diagnostic device. The system is currently in development and pending FDA clearance for commercial sale. The device targets healthcare facilities including primary care clinics, hospitals, surgery centers, and government/VA facilities.
- Diagnostic Testing Reagents and Consumables: Revenue from consumables used with the Merlin system including reagents for the comprehensive diagnostic menu covering Complete Blood Count, Lipid Panel, and Comprehensive Metabolic Panel tests. Ongoing consumable revenue typical of diagnostic device business models.
- CloudLab Software Services: CloudLab platform provides EMR integration and remote clinical lab scientist oversight, with potential for software-as-a-service revenue model. Results are automatically uploaded to EMR systems with quality verification.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Genalyte product offering
Product offeringCore offering
Genalyte develops and intends to commercialize the Merlin automated diagnostic system, a fully integrated point-of-care device combining rapid chemistry analysis, hematology analysis, and the proprietary Maverick immunoassay analyzer built on silicon photonic microring resonator technology. The system delivers lab-quality comprehensive blood test results (CBC, Lipid Panel, CMP) in under 30 minutes directly at the point of care, with results automatically uploaded to provider EMR systems through the CloudLab cloud platform. The platform has 31+ patents, 48 peer-reviewed publications, and has received the first-ever FDA clearance for a quantitative immunoassay (TSH) on a silicon chip.
Product overview
Genalyte offers a unified diagnostic platform consisting of three integrated components: Merlin (the fully automated point-of-care diagnostic system combining chemistry, hematology, and immunoassay testing), Maverick (the proprietary silicon photonic microring resonator biosensor technology powering immunoassays), and CloudLab (the cloud-based software platform enabling EMR integration and real-time quality oversight). The platform delivers lab-accurate results in under 30 minutes at point-of-care settings, covering comprehensive diagnostic menus including Complete Blood Count, Lipid Panel, and Comprehensive Metabolic Panel.
Differentiator
Problem solved
Functional benefit
Brands
- Merlin: The world's first real-time, all-in-one automated diagnostic system that delivers lab-quality results in under 30 minutes at point of care.
- Maverick
- CloudLab
Products and services
- Merlin Automated Diagnostic System Merlin is a fully automated, all-in-one point-of-care diagnostic system that integrates a rapid chemistry analyzer, hematology analyzer, and the proprietary Maverick immunoassay analyzer into a single self-running device. It delivers lab-quality results in under 30 minutes from up to 20 vials, with onboard refrigeration, secure waste containment, automated integrity checks for tube type, reagent integrity, and sample stability, and requires no plumbing, plugging into a standard wall outlet.
- Maverick Silicon Photonic Biosensor Platform Maverick is Genalyte's proprietary biosensor platform built on silicon photonic microring resonators that enables label-free, multiplex immunoassay testing. Each chip supports dozens of label-free immunoassays with over 100 micro-scale rings, each functionalized to detect a specific analyte. The platform captures full binding curves in real time for precise differentiation of true binding events and enables up to 26 tests to be run from one small sample without cross-reactivity.
- CloudLab EMR Integration Platform CloudLab is Genalyte's cloud-based software platform that integrates directly with provider EMR systems, enabling orders from the existing system and returning results the moment they are ready. Every result is quality-checked by clinical lab scientists in real time, routed automatically, and instantly available at the point of care, eliminating labeling errors and reducing mistakes from manual data entry.
Quantifiable outcome
- 25-42% of primary care patients skip labs when requested; 0% missed patients with same-visit testing using Merlin
- +6 more outcomes
Companies that use Genalyte
Customer profileSegments6 records
Ideal customer profiles6 records
Genalyte technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Genalyte partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Burjeel HoldingsflagshipStrategic partnership announced at Abu Dhabi Global Health Week 2025 for deployment of Genalyte's Merlin diagnostic system across Burjeel's network of hospitals and medical centers in the MENA region. Under the signed Letter of Intent, Burjeel plans to integrate the Merlin platform into its clinical infrastructure once regulatory clearance is achieved. The partnership underscores both organizations' commitment to advancing rapid, point-of-care diagnostics across diverse care settings including remote and underserved regions. Burjeel Holdings operates 100 assets including 19 hospitals, 29 medical centers, and 29 physiotherapy centers across UAE, Oman, and Saudi Arabia.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Genalyte competitors and assessment
Company assessmentBroad incumbents
- Abbott: Abbott operates i-STAT (POC) and Alinity (central lab) diagnostic platforms that compete directly with Merlin in chemistry, hematology, and immunoassay testing across hospitals and clinics globally.
- Roche Diagnostics: Roche's cobas platform spans central lab and POC immunoassays, competing with Merlin on test menu breadth and hospital-system deployments. Roche is the largest IVD player globally.
- Siemens Healthineers: Siemens Healthineers offers Atellica (central lab) and epoc (POC blood gas/chemistry) systems that overlap with Merlin's integrated chemistry/hematology/immunoassay approach for hospitals.
- bioMérieux (BioFire): bioMérieux's BioFire FilmArray and VIDAS lines span molecular diagnostics and immunoassays for clinical labs and hospitals, with overlapping menu and POC strategies to Merlin.
- Becton, Dickinson and Company (BD): BD's Veritor and FACS systems serve POC and clinical lab diagnostics markets, including immunoassays and rapid testing — comparable in channel, customer base, and recurring consumables economics to Genalyte.
Direct peers
- QuidelOrtho: QuidelOrtho markets Sofia and Triage point-of-care diagnostic systems focused on rapid immunoassay testing in clinics and urgent care settings — directly comparable to Merlin's POC positioning.
- Cepheid (Danaher): Cepheid's GeneXpert systems deliver rapid molecular diagnostics at POC, often with under-1-hour turnaround. Comparable to Merlin on speed-of-result value proposition in clinic and hospital settings.
- T2 Biosystems: T2 Biosystems develops rapid diagnostic panels using novel biosensor technology for clinical settings, with comparable FDA-cleared instrument-platform business model targeting hospital labs.
- EKF Diagnostics: EKF Diagnostics sells POC chemistry, hematology, and immunoassay analyzers (Quikread, Hemo Control) to clinics and small hospitals — a comparable compact POC diagnostic device peer to Merlin.
Emerging players
- Binding Site (Thermo Fisher): The Binding Site offers specialty immunoassay diagnostics (Optilite, SPAplus) for clinical labs. Comparable in immunoassay menu development and clinical diagnostics commercialization pathway.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Genalyte social profiles
Digital presenceGenalyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genalyte leadership team
Management profileNumber of profiles
Profiles11 records
Genalyte funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genalyte M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genalyte
What does Genalyte do?
Genalyte develops and intends to commercialize the Merlin automated diagnostic system, a fully integrated point-of-care device combining rapid chemistry analysis, hematology analysis, and the proprietary Maverick immunoassay analyzer built on silicon photonic microring resonator technology. The system delivers lab-quality comprehensive blood test results (CBC, Lipid Panel, CMP) in under 30 minutes directly at the point of care, with results automatically uploaded to provider EMR systems through the CloudLab cloud platform. The platform has 31+ patents, 48 peer-reviewed publications, and has received the first-ever FDA clearance for a quantitative immunoassay (TSH) on a silicon chip.
Is Genalyte a public or private company?
Genalyte is a private company. It is classified as venture growth investor backed and is currently operating.
When was Genalyte founded?
Genalyte was founded in 2007. It employs 51 to 100 people.
Where is Genalyte based?
Genalyte is headquartered in San Diego, United States, in the North America region.
How does Genalyte make money?
Three revenue lines are on record. Merlin Diagnostic Device Sales are the primary driver. The others are diagnostic Testing Reagents and Consumables and cloudLab Software Services.
Who are Genalyte's main competitors?
Broad incumbents on record are Abbott, Roche Diagnostics, Siemens Healthineers, bioMérieux (BioFire) and Becton, Dickinson and Company (BD). Direct peers are QuidelOrtho, Cepheid (Danaher), T2 Biosystems and EKF Diagnostics. Binding Site (Thermo Fisher) is listed as an emerging player.
Does Genalyte have an API?
No public API is recorded for Genalyte.
What industry is Genalyte in?
Genalyte's product category is Point-of-Care Diagnostic Systems. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 334516 and its SIC code is 3826.